Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Long-Term Deferred Tax (2017 - 2025)

Alterity Therapeutics has reported Long-Term Deferred Tax over the past 3 years, most recently at $25.2 million for Q2 2019.

  • For Q2 2019, Long-Term Deferred Tax fell 3.33% year-over-year to $25.2 million; the TTM value through Jun 2019 reached $25.2 million, down 3.33%, while the annual FY2019 figure was $25.2 million, 3.33% down from the prior year.
  • Long-Term Deferred Tax for Q2 2019 was $25.2 million at Alterity Therapeutics, down from $26.0 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $26.0 million in Q2 2018 and troughed at $25.2 million in Q2 2019.
  • A 3-year average of $25.5 million and a median of $25.3 million in 2017 define the central range for Long-Term Deferred Tax.
  • Biggest five-year swings in Long-Term Deferred Tax: rose 3.02% in 2018 and later fell 3.33% in 2019.
  • Year by year, Long-Term Deferred Tax stood at $25.3 million in 2017, then grew by 3.02% to $26.0 million in 2018, then decreased by 3.33% to $25.2 million in 2019.
  • Business Quant data shows Long-Term Deferred Tax for ATHE at $25.2 million in Q2 2019, $26.0 million in Q2 2018, and $25.3 million in Q2 2017.